StemCell Therapy

There are significant clinical differences and outcomes between patients with systemic sclerosis (SSc)-mixed connective tissue disease (MCTD), SSc-overlap, and SSc-only, according to research results published in Arthritis Care and Research. Study investigators indicated better survival among patients with SSc-MCTD and SSc-overlap than among those with SSc-only.

Mixed connective tissue disease is defined by the presence of anti-ribonucleoprotein complex (RNP) antibody with >3 clinical features, including swollen fingers, synovitis, myositis, Raynaud phenomenon, or acrosclerosis. Patients diagnosed with SSc and with features of connective tissue diseases are typically classified as SSc-overlap.

To describe the clinical characteristics and outcomes of SSc-MCTD and SSc-overlap, 1728 patients (86% women; 95% white) from the Australian Scleroderma Cohort Study who met the American College of Rheumatology/European League Against Rheumatism criteria for SSc were enrolled in the study. A total of 5.6% (n=97) of patients were indicated to have both SSc and MCTD (SSc-MCTD), while 7.3% (n=126) were indicated to have SSc-overlap syndrome.

Researchers created 3 mutually exclusive groups, including SSc-MCTD (n=97), SSc-overlap (n=126), and SSc-only (consisting of the remaining 1505 patients). Mean duration of follow-up was similar between groups at approximately 4.5 years. Researchers performed univariate comparison of clinical features between groups using analysis of variance or chi-square, and conducted survival analysis using Kaplan-Meier curves and Cox regression.

Results of the study indicated that among patients with SSc-overlap, 38.9% had overlap with rheumatoid arthritis, 34.1% with Sjogren syndrome, 13.5% with systemic lupus erythematous, 17.5% with polymyositis, and 2.4% with dermatomyositis. Compared with patients in the SSc-overlap and SSc-only groups, patients with SSc-MCTD group were younger at disease onset (46.5 and 46.8 years vs 38.4 years, respectively; P <.0001). Patients in the SSc-MCTD or SSc-overlap groups were more likely than patients in the SSc-only group to have other positive autoantibodies, including anti-Ro, anti-La, anti-Jo-1, and antineutrophil cytoplasmic antibodies. Patients in the SSc-MCTD and the SSc-overlap groups had similar frequency of interstitial lung disease (ILD), whereas those in the group with SSc-MCTD had higher frequency of pulmonary arterial hypertension (PAH; 12.4% vs 4.8% and 11.1% in the SSc-overlap and SSc-only groups, respectively; P =.0751). Synovitis and myositis were equally common in the SSc-overlap and SSc-MCTD groups.

Patients with SSc-overlap were significantly more likely to have experienced dysphagia (60.3% vs 45.4% of SSc-MCTD vs 45.5% of SSc-only; P =.0006). Compared with patients in the SSc-only group, those in the SSc-MCTD and SSc-overlap groups had a higher likelihood of exposure to immunosuppressive treatment, including prednisolone and disease-modifying antirheumatic drugs.

Kaplan-Meier curves showed better survival in the SSc-MCTD group compared with patients in the SSc-overlap or the SSc-only groups (P =.011); however, scleroderma-specific antibodies that were more reliable indicators of survival indicated that antinuclear antibody-centromere or anti-RNP conferred consistently better survival than anti-topoisomerase 1 (Scl)-70 or anti-RNA polymerase 3. Researchers noted that compared with patients with SSc-only, those with SSc-MCTD or SSc-overlap had lower all-cause mortality after ILD and PAH diagnosis (P =.024). Overall, compared with SSc-only, SSc-MCTD and SSc-overlap groups combined had significantly better survival (P =.019).

Study limitations included survivor bias, retrospective analysis, and a small SSc-MCTD sample size for the subgroup analysis.

This study provides insights into the clinical characteristics of patients with SSc-MCTD, SSc overlap, and SSc-only, and shows that anti-RNP antibodies are associated with better survival than anti-Scl-70 and anti-RNA polymerase [3] antibodies, the researchers concluded.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Fairley JL, Hansen D, Proudman S, Sahhar J, Ngian GS, Walker J. Clinical characteristics and survival in systemic sclerosis-mixed connective tissue disease and systemic sclerosis-overlap syndrome [published online February 14, 2020]. Arthritis Care Res. doi:10.1002/acr.24167

Read the original post:
Better Survival in Patients With SSc-Mixed Connective Tissue Disease and SSc-Overlap vs SSc-Only - Rheumatology Advisor

Libby Smith should be looking forward to her school prom and preparing to take her GCSEs.

Instead, she feels "trapped" in the body of an 80-year-old and needs two knee cap replacements, thanks to a rare form of juvenile arthritis

According to YorkshireLive , the 16-year-old is constantly in pain from juvenile idiopathic arthritis (JIA), so bad that she has considered undergoing a risky bone marrow transplant in an attempt to 're-set' her immune system.

The condition targets Libby's cartilage, making even the simplest of tasks difficult to complete.

Walking, cutting up food and even brushing her hair are now impossible for Libby- she has to rely on her parents Diane Smith, 40, and Adrian Smith, 45, for help.

JIA is an inflammation of one or more joints in a child under the age of 16 years.

Juvenile means that the child was under 16 when the arthritis started, idiopathic means there is no other explanation for the inflammation in their joints and arthritis means that there is swelling and inflammation in the childs joints.

The child's immune system becomes over-active or poorly controlled.

As a result, it starts to attack the lining of the joint which causes inflammation and swelling. Infection can also be a trigger.

Can be more likely in children with a family history of rheumatoid arthritis or lupus.

Information taken from National Rheumatoid Arthritis Society

The teen wanted to become a professional dancer or swimmer, but her dreams were snatched from her when she was first diagnosed with the condition at just 5 years old.

Libby has suffered with mobility issues, having to undergo a lot of surgeries in her lifetime- including a fusion surgery on her right foot, and having an Ilizarov leg brace fitted; she also needs two knee replacements.

Libby is forced to hobble around her home, 'shuffle' downstairs on her bum and has to go out in a wheelchair as her wrists are too weak to use crutches.

The teen, from West Yorkshire, said: "It feels like I'm trapped in an older person's body, I feel like I'm in a hole that I can't get out of.

"I'm waiting for operations to make life easier that are associated more with grandparents - people in their 70s and 80s - rather than my own age.

"I'm upset all the time and I struggle to sleep at night.It's like constant shooting pains that burn, I just want the knee replacement done as soon as possible.

"I've not completed a single day of highschool and struggled with friends as I think people just don't understand.

"It's been really isolating not going to school.It's been frustrating going through this, you get your hopes up that people with JIA grow out of it but I think it just got worse."

Some people with JIA grow out of' the condition, but Libby has not been so lucky and her health continues to deteriorate.

Mum, Diane, says watching Libby's health continue to deteriorate is "breaking her heart" and she turned to social media for answers and support.

The diet consultant said that Libby had always complained of aching legs but only got a official diagnosis in 2011 after Adrian insisted on taking her to A&E when the tot avoided putting any weight on her right leg.

Diane said: "Libby was absolutely fine as a baby but as she got older she would say to me 'I can't walk' and would say her legs were aching all the time.

"She would complain all the time, we just thought she was downright lazy.

"As she was our first child we didn't have anything to compare her to, we just thought that she had little legs and was tired.

"One Sunday when she was five she hopped round on her left leg all day. Adrian told me to pack a bag and that he was taking her to A&E.

"I told him we couldn't take her there as it wasn't an accident or an emergency but he insisted if she couldn't walk he was taking her."

After a week of blood tests and x-rays, Libby finally received her diagnosis of JIA.

Diane said: "We were told it was a childhood condition that she should grow out of in her teens as she goes through puberty.

"They said if she didn't grow out of it then she would probably grow out of it when she had her first baby because things change with hormones.

"She was measured up for crutches, a wheelchair and a walking frame and had physio organised.

"The only history we have of it in our family is with older people, like everyone's family, nan and grandad had it a bit.

"Felicity (Libby's 10-year-old sister) is the complete opposite of Libby, she's the most active child in the country so we knew there was no problem there.

"If we'd had Felicity first and knew how active a child should be, we would have realised there was something wrong with Libby a lot sooner."

Libby's arthritis only worsened as she got older, leaving her unable to attend secondary school- instead, she battled through the pain to study with tutors at home.

Diane said: "She missed her whole high school life because she was so poorly - since leaving junior school her condition got worse and worse.

"We've had English and maths tutors at home but some days I'd have to turn the tutor round at the door and say she wasn't well enough.

"Some days she would manage an hour and other days she could do two, but not very often."

The teen's physical limitations and absence from school means Libby cannot sit her GCSEs.

However, Diane and business owner Adrian encouraged her passion for make-up and she set up her own make-up artist business last year.

Diane said: "Libby's not able to sit her GCSEs as she's missed far too much school because she just wasn't well enough.

"As parents we've been realistic and thought about what she would be able to do as an adult.

"Libby is really good at make-up artist work so we set up a business for her and recently swapped her English and maths tutors for make-up artist tutors.

"She's had a few clients but since Christmas she's just not been well enough, so we've had to put the business on hold."

Libby is on a lot of medication and has undergone a lot of surgeries to combat her painful symptoms- but none of the treatments appear to be working in the long term.

Business owner, Adrian said: "The consultants describe Libby as 'not following the script'.

"Instead of her body accepting medicines that have been successful for other people, it rejects it.

"Libby was looking into a bone marrow transplant to re-set her immune system not so long ago because they were running out of ideas as far as treating it with normal medications.

"The doctors were very blunt about the risks and said she might not make it, there was a substantial percentage that we'd lose her.

"It wasn't because of the procedure, but because of the bacterial medication she's on that increases the risk of her not coming through the re-setting of her immune system.

"We were on the last family of medicines before Christmas and it started working so she decided she wouldn't go ahead with it."

The family are desperately searching for a medicine or treatment that can help Libby's condition.

Adrian said: "This condition is something you associate with someone who's a lot older - she's having to face issues that 80-year-olds face at the age of 16.

"She hobbles around the house, going up and down stairs she does on her bum."When she walks it's more like a shuffle, a move that older people do, and when we go out she has to use the wheelchair.

"She used to be able to brush her hair but we have to do it now, we also cut her meat up for her before she can eat.

"All these other kids her age are off on school trips and going out with friends after school but Libby can't do that.

"As parents we try and do what we can to spend time with her and make her laugh.

"I've said all along that if there was something overseas I would pay for it, we just want answers.

"Sod the funding, if it makes me bankrupt, I'll pay for it."

Continue reading here:
Teenager with rare juvenile arthritis 'feels trapped' in the body of an 80-year-old - Gloucestershire Live

Scorpion venom could be used to manage arthritis symptoms in the future, according to new research published in the journal Science Translational Medicine.

Scientists suggest that a protein present in scorpion venom could help alleviate the harmful side effects of steroids used to treat arthritis.

Testing on mice, US researchers found this protein rapidly accumulates in joint cartilages, including the knees, ankles, hips, shoulders and spinal discs. They combined these proteins, known as cystine-dense peptides (CDPs), with a steroid normally used to treat rheumatoid arthritis to create a drug delivery system that targeted only the joints and not the rest of the body.

They found that this method reversed joint inflammation in the rodents, while avoiding steroid exposure to other parts of the body.

A 'safer way' to treat arthritis

The team hope that the findings will help a lot of people, providing a 'safer way' to treat the some 10 million sufferers of arthritic diseases in the UK, and 54 million in the US.

While steroids are used to treat inflammation that causes arthritis, they come with dangerous side effects, including weakening of the bones, high blood pressure and increased risk of infections, which is why they cannot be administered for long periods of time.

Dr Jim Olson, of the Fred Hutchinson Cancer Research Centre in Seattle, US, and the senior scientist in the project, said, For people with multi-joint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself.

Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

The researchers looked at cystine-dense peptides (CDPs), a chemically diverse family of proteins found in the venom of scorpions, spiders and snakes.

Treatment reversed inflammation in the joints without damaging tissue

After analysing 42 CDPs from 20 species, they identified one candidate that accumulated within cartilage tissue in rodents.

The scientists then attached these proteins to triamcinolone acetonide, a steroid treatment for arthritis, and found that it helped concentrate the steroid drug within the cartilage of joints in rats with rheumatoid arthritis.

In rheumatoid arthritis, the body's immune system targets affected joints, which leads to pain and swelling.

The treatment was found to reverse inflammation in the joints without damaging tissues in the thymus and spleen, the two organs often affected by repeated steroid treatments.

Researchers say further studies are required to assess the safety of this drug delivery method in animals over longer periods of time before moving on to human clinical trials.

Emily Girard, staff scientist in Dr Olsons laboratory and one of the studys lead authors, said, "There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people."

More here:
Scorpion venom might be the answer to treating arthritis - here's how it works - Lancashire Post

A decade-old drug used to treat inflammation in arthritis patients could be the answer to the world's fears of the coronavirus.

Actemra, an anti-inflammation drug made by Swiss drugmaker Roche, has been approved by the Chinese government to treat severe coronavirus symptoms. This comes at a time when countries around the world are desperately searching for ways to combat the deadly infection.

The Swiss drug maker donated nearly $2 million worth of Actemra to China, its local operations said in a blog post on Monday.

According to reports, 14 serious and critically ill patients treated with existing medicines at a hospital affiliated with the University of Science and Technology of China (USTC) showed positive results.

Since Actemra's approval a decade ago, it has become the go-to drug for inflammatory conditions, including cytokine storms in cancer patients receiving cell therapy.

The Swiss company, for which China is its No. 2 market behind the United States, is also making diagnostic gear to detect the coronavirus.

Currently, there is no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany, and India.

Read the original here:
Coronavirus medicine: An arthritis drug could be the answer everyone is looking for - Economic Times

Scorpion venom could mitigate the risks of steroids (Jamras Lamyai / EyeEm Provider: Getty Images)

The key to managing arthritis may be found in scorpion venom.

In a roundabout way, the venom could be used to help elderly people and others suffering with the disease.

Scientists suggest that a protein present in scorpion venom could help mitigate the harmful side effects of steroids used to treat arthritis.

Researchers in the US have found this protein rapidly accumulates in joint cartilages, including the knees, ankles, hips, shoulders, and spinal discs, when administered on mice.

The team combined these proteins, known as cystine-dense peptides (CDPs), with a steroid normally used to treat rheumatoid arthritis to create a drug delivery system that targeted only the joints and not the rest of the body.

They found that this method reversed joint inflammation in the rodents, while avoiding steroid exposure to other parts of the body.

The researchers believe their drug delivery method could be a safer way to treat arthritic diseases, which affect more than 10 million people in the UK.

While steroids are used to treat inflammation that causes arthritis, they come with dangerous side effects, including weakening of the bones, high blood pressure and increased risk of infections, which is why they cannot be administered for long periods of time.

Dr Jim Olson, of the Fred Hutchinson Cancer Research Centre in Seattle, US, and the senior scientist in the project, said: For people with multi-joint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself.

Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

The researchers looked at CDPs, a chemically diverse family of proteins found in the venom of scorpions, spiders and snakes. After analysing 42 CDPs from 20 species, they identified one candidate that accumulated within cartilage tissue in rodents.

The scientists then attached these proteins to triamcinolone acetonide, a steroid treatment for arthritis, and found that it helped concentrate the steroid drug within the cartilage of joints in rats with rheumatoid arthritis.

The treatment was found to reverse inflammation in the joints without damaging tissues in the thymus and spleen, the two organs often affected by repeated steroid treatments.

Researchers say further studies are required to assess the safety of this drug delivery method in animals over longer periods of time before moving on to human clinical trials.

Emily Girard, staff scientist in Dr Olsons laboratory and one of the studys lead authors, said: There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people.

The findings are published in the journal Science Translational Medicine.

Read the original:
Hope for better arthritis treatment could be found in scorpion venom - Metro.co.uk

They mightn't seem like the most obvious places to look, but the venom of deadly creatures like spiders, snakes and scorpions are an increasingly rich source of medicines for human health. The latest example of this comes from scientists at Fred Hutchinson Cancer Research Center, who have discovered a tiny protein in scorpion venom that could become part of a potent new treatment for arthritis.

While drugs exist to treat inflammation in sufferers of arthritis, a scattergun approach means that the often bring severe side effects. These types of non-targeted steroid treatments sweep through the whole body and while they can act swiftly to relieve inflammation, they can also cause high blood pressure or weight gain, and make it harder for diabetics to manage their condition, to list a few examples.

For people with multijoint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself, says Dr. Jim Olson, who led the new research. Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

This strategy Olson speaks of is the product of more than a decade of toiling away in the lab, searching for proteins in scorpion venom that can be used as the basis for advanced drugs to treat various ailments. Around four years ago while screening dozens of peptides from the venom of scorpions and spiders, he and his team found one that seemed to naturally buildup in the cartilage.

This struck the scientists instantly as a potential way to develop more targeted treatments for arthritis. This led to years of trial and error and more tinkering in the lab, until the researchers came up with a recipe that appears to have the desired effect. It involved pairing this peptide with a steroid called triamcinolone acetonide, a combination that was then tested in rats where it proved capable of concentrating in the joints and reversing inflammation in rats with arthritis. And crucially, it produced no detectable side effects.

Its a pretty simple idea to take a mini-protein that naturally goes to cartilage and attach something to it so that you get targeted delivery of the drug, but it was challenging to accomplish, said Emily Girard, a staff scientist in Olsons lab. We had to learn and adapt the behavior of the mini-protein, the chemical linker and the steroid payload to make a product that would go to cartilage, stay as long as we needed it to, release the drug at the right rate, and have a local but not systemic effect. There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people.

The scientists note that the treatment is still years away from entering clinical use, but describe the proof of concept as "promising."

The team's research was published in the journal Science Translational Medicine.

Source: Fred Hutchinson Cancer Research Center

Read the rest here:
Scorpion venom protein reverses inflammation in rats with arthritis - New Atlas

Why do microbes kill some people but not others? This is the hardest question in all of medical microbiology. The reason it's so hard is because the answer depends not just on the microbe in question but also on the person.

Sometimes, it's because the microbe is particularly nasty. No matter how healthy a person is, smallpox, HIV, Ebola, cholera, and plague all wreak havoc on the human body.

But that's not the case for all microbes. Billions of people get scratched every year, but only a handful will develop an infection with a flesh-eating bacterium. Millions of people go swimming in lakes every year, but only a handful will become infected with a brain-eating parasite. Why? Is it simply "wrong place, wrong time," or is there a more sophisticated answer?

Increasingly, the latter appears to be true. As a case-in-point, scientists discovered that a single mutation (i.e., a single letter change in our 3-billion-letter genome) may have doubled a person's risk of becoming infected with the 2009 pandemic strain of influenza. In other words, an individual's genetics -- particularly when it comes to genes involved with the immune system (as was the case in the flu research) -- may be just as much to blame as the microbe's genetics.

How an Arthritis Drug Could Treat Coronavirus Infections

An effective immune response must be of the proper strength and directed at an appropriate target. If these two criteria aren't met, bad things can happen, such as autoimmune disease or a lethal over-reaction to a peanut. The same is true when the immune system targets a dangerous microbe. The response must not be too weak or too strong. If it's too weak, the microbe will overcome the body; if it's too strong, the body can suffer from collateral damage.

One way collateral damage can occur is when the immune system sends out too many pro-inflammatory signals. The immune system is constantly "talking" to other parts of the immune system using chemical messengers known as cytokines. Some encourage inflammation, others discourage it. If too many pro-inflammatory cytokines, such as one called interleukin-6 (IL-6) are released, a "cytokine storm" is said to have developed.

Typically, IL-6 is deployed in order to elicit a quick response to infection and tissue injury. But if too much is produced, the entire body can undergo an inflammatory response, which can be lethal if it leads to multiple organ failure. Ultimately, it's this sort of system-wide immunological overreaction that causes people to die from septic shock. It may also be responsible for some of the deaths due to influenza and SARS.

Something similar may be happening with people who become infected with the Wuhan coronavirus and develop the disease now known as COVID-19. Perhaps they have an immunogenetic profile that, for some reason, overreacts to the virus. Thus, a drug that targets IL-6 could, in theory, help block an overreactive immune response.

And that's precisely what China has just discovered. An antibody drug that blocks IL-6 receptors (called Actemra or tocilizumab) has shown promise in treating patients in Chinese clinics. FiercePharma explains that this drug was approved by the FDA in 2017 to treat cytokine storms and in 2010 to treat rheumatoid arthritis, an autoimmune condition. What causes that? You guessed it: Too much IL-6.

Let's hope this drug helps save some lives.

See the original post here:
How an Arthritis Drug Could Treat Coronavirus Infections - American Council on Science and Health

More News08 Mar 2020 | 4:31 PM

Puducherry, Mar 8 (UNI) Mr M Sankaranarayanan, Managing Director, The Grand Technologies and Founder-cum-Chairman of Aathmalayaa School, Karaikal has been elected as the Chairman of Confederation of Indian Industry (CII), Puducherry State Council for the financial year 2020-21.

Ahmedabad, Mar 8 (UNI) Jewelry sector expert and the Chairman and Managing Director (CMD) of Headway Business Solutions LLP, Gujarat based company in to consultancy, coaching and mentoring for jewelry sector business development, Paresh Rajpara on Sunday said that the biggest challenge in the gems and jewelry sector in India was the gold price volatility.

BEIJING, March 8, 2020 /PRNewswire/ -- Forty-eight hours ahead of schedule, Sinopec Corp, China's leading energy and chemical company, put its first melt-blown non-woven fabric assembly line into operation at its Yanshan factory in Beijing on March 6. The Yanshan factory is a converted 3600 square meter old warehouse that has found new life as a global production base following the challenges brought by the coronavirus outbreak.

NEW DELHI, India, March 7, 2020 /PRNewswire/ -- IPM India Wholesale Trading Private Ltd (IPM India), a country affiliate of Philip Morris International Incorporation (PMI), has announced that it has set an aim to achieve as much as 40% equal gender representation in management roles in the company by 2022. A more focused journey began for IPM India in 2015 with the introduction of target Gender Representation KPIs. The company took a firm decision to take up the gender representation KPI from 18 percent in 2015 to 40 percent by 2022.

Kolkata, Mar 07 (UNI) Abhijit Roy, Managing Director and CEO of Berger Paints India Ltd., has been elected as the chairman of CII Eastern Region for 2020 21.

See the rest here:
Rising arthritis: Shalby hospital to come up in UP - United News of India

Higher levels of consumption of ultra-processed food in patients with rheumatoid arthritis (RA) have been associated with worse metabolic profiles and elevated cardiovascular risk, while higher levels of consumption of unprocessed or minimally processed foods are associated with lower low density lipoprotein (LDL) cholesterol and reduced 10-year cardiovascular disease risk, according to study results published in Clinical Rheumatology.

To assess the associations between processed food consumption and risk factors for cardiovascular disease in patients with RA, investigators in Sao Paulo, Brazil, conducted a cross-sectional study with 56 women (aged 62.57.9 years; body mass index, 28.45.1 kg/m2) focused on evaluation of food consumption according to level of processing (eg, unprocessed or minimally processed, processed, and ultra-processed) and associated levels of consumption of processed foods with risk factors for cardiovascular disease.

Unprocessed or minimally processed was the most prevalent food processing level in the study participants (42.612.6% of total energy intake [TEI]), followed by processed (24.211.9% TEI), ultra processed (18.111.8% TEI), and culinary ingredients (15.16.4% TEI). Adjusted regression models showed a negative association between higher consumption of unprocessed or minimally processed foods and Framingham risk score (=-0.07 [95% CI, -0.14 to -0.006]; P =.034), 10-year risk of developing cardiovascular disease ( =-0.07 [95% CI, -0.12 to -0.02]; P =.013) and LDL (=-1.09 [95% CI, -1.94 to -0.24]; P =.014). A positive association was found between higher consumption of ultra processed foods and glycated hemoglobin (=0.04 [95% CI, 0.01-0.07]; P =.013). After adjustments were made for age and body mass index, the association between unprocessed or minimally processed foods and Framingham risk score was no longer significant. In contrast, after adjustments, the association between higher consumption of ultra processed foods and Framingham risk score became significant (=0.06 [95% CI, 0.001-0.11]; P =.045).

Study investigators concluded, Patients with RA consuming more ultra-processed foods showed higher glycated hemoglobin and Framingham risk score, whereas those consuming more unprocessed or minimally processed foods had lower 10-year risk of developing cardiovascular disease and LDL. A food pattern characterized by a high ultra-processed food consumption emerges as a novel, modifiable risk factor for cardiovascular diseases in RA. Prospective, controlled studies should address this hypothesis.

Reference

Smaira FI, Mazzolani BC, Peanha T, et al. Ultra-processed food consumption associates with higher cardiovascular risk in rheumatoid arthritis [published online January 4, 2020]. Clin Rheumatol. doi:10.1007/s10067-019-04916-4

This article originally appeared on Rheumatology Advisor

Read more:
Ultra-Processed Food Consumption Linked to Cardiovascular Risk in RA - The Cardiology Advisor

Editors Note: Sponsored content brought to you by Panorama Summit Orthopedics

Shoulder pain can range from temporary to long-lasting, from motion-related to constant, but one of the most disruptive symptoms of any shoulder injury is its effect on sleep.

When you dont sleep, everything in life becomes harder, said Dr. Aaron Black, a shoulder, knee and trauma specialist at Panorama Summit Orthopedics.

Some of the most common sources of shoulder pain include rotator cuff injuries and arthritis. In Summit County, its common to see patients who develop shoulder arthritis as a result of previous injuries to the shoulder, such as a shoulder dislocation earlier in life, Dr. Black said.

A specific diagnosis and treatment plan can result in years or perhaps a lifetime of pain relief and increased mobility in this important joint. Its Dr. Blacks mission to make sure hes helping patients not only eliminate shoulder pain and weakness, but also get back to consistently healthy and restful sleep.

Primary arthritis vs. rotator cuff arthropathy

The two broad categories of arthritis most commonly seen in Summit County are primary arthritis and rotator cuff arthropathy, or secondary arthritis. Primary arthritis has no specifically known cause and is usually related to age, sex and genes, according to the Arthritis Foundation. Rotator cuff arthropathy happens after a large, long-standing rotator cuff tendon tear that no longer holds the head of the humerus in the socket, causing it to move upward and damage the surface of the bones, according to the American Academy of Orthopaedic Surgeons.

Shoulder arthritis is experienced as achy pain and stiffness around the shoulder that often feels worse in the morning, Dr. Black said. Rotator cuff arthropathy is usually associated with stiffness and weakness.

Nonoperative arthritis treatment

Nonoperative shoulder arthritis treatment includes physical therapy and injection therapies.

As with any arthritic joint, the more you use it, the less stiff it is and the less pain you have, Dr. Black said.

PT can help improve range of motion in the shoulder, while icing the shoulder two or three times a day can reduce inflammation and ease pain.

Dr. Blacks injection therapy options include cortisone and biologic agents, such as platelet-rich plasma (PRP), all of which act primarily as anti-inflammatories.

No biologic injection therapies contain stem cells for tendons or cartilage, despite advertisements to the contrary, and thus do not regrow cartilage or tendons, he said.

Cortisone injections can offer pain relief for three to six months, while PRP tends to last a bit longer, Dr. Black said. The procedures are performed in the office under ultrasound guidance.

Shoulder joint replacement (arthroplasty)

If shoulder arthritis is severe, its less likely that the nonoperative options will get the job done. The next option for these patients would be shoulder joint replacement surgery.

Dr. Black said there are two types of shoulder replacements: anatomic total shoulder replacement and reverse total shoulder replacement. There are roughly 53,000 of these surgeries performed each year in the United States, according to the American Academy of Orthopaedic Surgeons.

Both procedures have differing benefits. Dr. Black said that anatomic replacements can be done on patients of any age, but those who have it at a younger age might require another surgery later in life. The procedure works well for getting patients back to their normal activities.

Reverse replacements are extremely reliable for reducing or eliminating pain, but less reliable for getting full range of motion back, he said.

I do all of my shoulder replacements with custom 3D modeling and patient-specific guides made to ensure the components are in exact right position, Dr. Black said.

Dr. Black stresses that all joint replacements are elective surgeries.

I will never tell a patient they have to have a joint replacement, he said. This is symptom-based when you say its time, its something Ill say you should have. I want all of my patients to be informed about the options.

Shoulder joint replacement recovery includes about six weeks in a sling, and in three to four months most patients are back to regular activity with continued improvement from there.

Rotator cuff injuries

Another common local shoulder affliction is to the rotator cuff, which is the combination of muscles and tendons that keep your arm bone centered in your shoulder socket to provide shoulder motion and stability. Dr. Black said these injuries can happen during a fall when the arm is thrown away from the body, but sometimes rotator cuff injuries are chronic and happen over time.

Some people even have large tears to the rotator cuff without ever feeling any symptoms.

The good news is that there are a lot of treatment options, from physical therapy and injections to repair or reconstruction surgery.

Read the original post:
Common sources of shoulder pain and how to treat it - Summit Daily News

CHICAGO About 54 million Americans suffer from the aches and pains of arthritis.

Treatments range from pain medications to injections to surgery.

None of it seemed to work for 77-year-old Marty Ciesielczyk.

And it jeopardized something he loved: jogging.

"For me, it's just enjoyable, and if you're not a runner, then you would have no idea what I'm talking about."

But Marty's active lifestyle was in jeopardy when knee pain took over.

"When you got to lay on the floor to get dressed, it's tough."

It happens when there's a loss of cartilage in the joint.

"It's like a tire, and as you slowly lose rubber on the tire, it wears away," explained Dr. Adam Yanke, a surgeon with Midwest Orthopaedics at Rush University.

"You might need to have the tire replaced at some point."

Marty's arthritis was too advanced for a scope procedure but not bad enough for a joint replacement.

So he enrolled in a study testing whether amniotic fluid, which surrounds a growing baby in the uterus, could help his pain.

"Amniotic products come from patients that are having healthy, elective C-sections, and they choose to donate these products at the time of the delivery," said Dr. Yanke.

It's thought to increase tissue healing and lower inflammation.

Doctor-diagnosed arthritisis more common in womenthan in men. Arthritis and other joint disorders are among the five most costly conditions among adults 18 and older.

Your bone marrow makes mesenchymal stem cells, or MSCs. They are known to grow into new tissues, including cartilage.

By gathering these cells and injecting them into the knee joint, the hope is that they will give growth to new cartilage and reduce inflammation.

Marty received a placebo during the study, but then chose to have the amniotic fluid when the study ended.

"I mean I didn't care if it was Pixie dust, as long as my knee was going to feel better."

He went from not being able to get dressed to jogging about a week after having the injection.

"This morning, I ran three, three miles, and I had no problem at all."

Amniotic fluid is also being used to treat ulcers in the eye.

Rush University will be enrolling patients for a larger follow-up study on amniotic fluid for joint pain in the future.

Clinical trialsare still going on and most studies are still early.

A review published in 2016 in BMC Musculoskeletal Disorders concluded that MSC-based therapies offer an "exciting possibility" for treatment, but further studies need to be done on how they can best be used and how well they work.

They are also known to be very expensive.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

Excerpt from:
YOUR HEALTH: Knee relief can be found in the womb - WQAD.com

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about what rheumatologists and patients believe is the most important in rheumatoid arthritis treatment, the effects of acute kidney injury on hip arthroplasty complications, the best technique for traumatic finger amputation, and seasonal effects on symptoms including fatigue on primary Sjgrens syndrome.

A new study assessed the preferences of patients and rheumatologists regarding treatment attributes for rheumatoid arthritis (RA) as well as their feelings regarding shared decision-making. Three steps were taken: literature review, RA patient focus group discussion, and rheumatologist focus group discussion. A total of 90 rheumatologists (mean years of experience, 18.1 years; 52.2% were female; average RA patients per week, 24.4) and 137 RA patients (mean age, 47.5 years; 84.0% were female; mean time since RA diagnosis, 14.2 years; mean time in treatment, 13.2 years) were included in the study. Although the top three attributes were the same between patients and rheumatologists, the order in which they were ranked differed, with patients placing the highest value on time with optimal quality of life (QoL) followed by mode of administration and time to onset of treatment action, compared to rheumatologists, who ranked the top three attributes as mode of administration, time with optimal QoL, and time to onset of treatment action.

A new study highlighted the effects of acute kidney injury (AKI) on complication risk in total hip arthroplasty (THA) patients. The study authors concluded that AKI significantly increases postoperative complication risks, including mortality, and recommend that increased focus be placed on reducing AKI risk. A total of 4.1 million primary THAs were performed during the study period, of which 61,077 (1.5%) included AKI during hospitalization. Unadjusted analyses unearthed a correlation between AKI and higher rate of complications and healthcare utilization. When adjusting for age, gender, race, income, underlying diagnosis, medical comorbidity, and insurance payer, AKI presenting in primary THA was significantly increased risks for implant infection, transfusion, revision, death, total hospital discharges above the median, discharge to a rehabilitation facility, and hospital length of stay longer than three days.

A new study examined whether season has an impact on symptoms of fatigue, pain, and dryness in primary Sjgrens syndrome. The present study evaluated patient data from the French nationwide multicenter pSS cohort Assessment of Systemic Signs and Evolution in Sjgrens Syndrome (ASSESS) (n=395). ASSESS was created in 2006 and houses five-year prospective follow-up data as well as data from three randomized, placebo-controlled trials of infliximab, rituximab, and hydroxychloroquine. In each study, visits included data collection on visual analog scale (VAS) scores for pain, fatigue, and dryness. Data were assessed by the day, month of the year, and season. VASs did not largely differ among the seasonal groups. The EULAR Sjgrens Syndrome Patient Reported Index scores did not significantly differ by season: spring, 57.7; summer, 59.5; fall, 55.9; and winter, 57.2.

A study questioned which is the best strategy to employ in traumatic finger amputations and concluded that the target technique will depend on the patient. The researchers reviewed data from a retrospective cohort study who underwent revision amputation or replantation at 19 U.S.- and Asia-based centers between Aug. 1, 2016, and April 12, 2018. The present analysis included data on 185 patients. The primary outcomes were hand strength, dexterity, hand-related quality of life, and pain, and the study authors employed a tree-based statistical learning method to obtain clinical decision rules for traumatic finger amputation treatment. Implementation of the tree-based statistical learning estimates found that different strategies were associated with different outcomes. Maximal hand dexterity or minimal patient-reported pain was obtained through replantation. Maximal hand strength was obtained through revision amputation in the case of a single-finger amputation; in all other cases, replantation was the best approach. Maximal patient-reported quality of life was obtained through revision amputation in patients with dominant hand injuries, and replantation was favorable in the case of nondominant hand injuries.

Read more here:
Rheum Round-up: Heres What Rheumatologists and Patients Value in Rheumatoid Arthritis Treatment, Plus How Kidney Injury Affects Surgery Complications...

captionGout is associated with frequent joint pain.sourceljubaphoto/Getty Images

Gout is an intensely painful form of arthritis that affects over 8 million Americans. As our diets change to include more processed foods, and with the increase in popularity of high protein diets, gout is on the rise, especially for older men. Heres what you need to know about the causes, symptoms, and treatment for gout.

Gout causes your joints to swell up and become extremely painful. Its the most common type of inflammatory arthritis and is caused by a buildup of uric acid, a waste product that is produced when your body breaks down a chemical called purine in certain foods.

Gout is caused by a condition called hyperuricemia, which means there is an excess of uric acid in the blood. Uric acid is normally diluted in your blood and leaves the body through your urine, but when you have too much uric acid in your blood, the acid can crystallize and build up in your joints, causing gout symptoms.

Foods with high concentrations of purines include red meat, alcohol, and fruit juices even if they are naturally sweetened. In addition, seafood like sardines, tuna, and shellfish also contain purine and should be eaten only in moderate amounts. Read our article on the best diets for gout for more information on what you should be eating and avoiding.

Western-style dietary patterns seem to increase the risk of gout, says Hyon K. Choi, MD, a professor of Medicine at Harvard Medical School. A typical Western diet includes large amounts of processed carbohydrates like high fructose corn syrup, red meat, and saturated fats.

Obesity may also be a risk factor: A study, published in Arthritis Care & Research in 2012, found that people who are obese are around twice as likely to suffer from gout compared with people whose body mass index falls in the normal range.

Other risk factors include sex and age. Men are more likely to develop gout, in general, and women are at greater risk after menopause.

Some people may only have gout attacks periods of acute pain and swelling in joints once or twice in their lifetime, while others with chronic gout may have frequent attacks, several times a year, that dont fully heal in between episodes.

Some of the most common symptoms of gout are:

The symptoms of gout usually come and go, says Choi, although patients can have chronic joint pain if the gout is severe or longstanding.

When you have an acute attack of gout, your doctor will likely focus on treating your immediate symptoms first by prescribing non-steroidal anti-inflammatory drugs to help bring down the pain and swelling. For patients who get frequent flares of gout, long-term treatment with a medication that lowers uric acid levels, such as allopurinol, is recommended, Choi says.

However, while symptoms of gout can be controlled with medications, it is also important to implement lifestyle changes, Choi says, adding that a good place to start is adopting a healthy diet and exercise.

Left untreated, gout can increase your risk of developing heart disease, type 2 diabetes, and chronic kidney disease.

Over the long term, losing weight may be an important step to treat gout, as being overweight increases your chances of developing gout. However, you should avoid extreme dieting, as losing weight too quickly can actually trigger gout attacks.

Avoiding high purine foods can help lower uric acid in your body, and consuming certain foods like vitamin C and coffee may help treat gout, according to some research.

Choi says that overall, the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets seem to be beneficial for patients with gout. This means adding more whole grains, vegetables and fruits, and legumes to your diet and eating less meat. For more information about what to eat for each of these diets, check out our articles about the Mediterranean diet and the DASH diet.

Gout can be painful in the short term and can lead to serious illnesses in the long term, but there are treatments available to lower your risk. The best place to start is to talk to your doctor about diet and lifestyle changes you can make to improve your health.

More here:
What is gout? How to know if you have it and recommended treatment - Business Insider

Rheumatoid Arthritis and Lupus Treatments Market with Key Business Insights

Global Rheumatoid Arthritis and Lupus Treatments Market report is a comprehensive study of the market and the growth prospects in the market. The information offered in the report has been accumulated through both primary and secondary sources of data collection and also through interviews of industry experts. The study is an exhaustive database of authentic and relevant information that readers, researchers, analysts, and executive professionals for the purposes of academic or commercial research on the market can use to their benefit. The report includes essential market aspects like industry trends, segmentation, growth prospects, promising opportunities, prevalent growth trends, challenges, and competitive analysis.

Click Here to Access a PDF Copy of the Sample Rheumatoid Arthritis and Lupus Treatments [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/53445

A conscious effort is made by the subject matter experts to analyze how some business owners succeed in maintaining a competitive edge while the others fail to do so makes the research interesting. A quick review of the realistic competitors makes the overall study a lot more interesting. Opportunities that are helping product owners size up their business further add value to the overall study.

Leading Players studied in this report are as follows:

AbbVieAmgenBayerBiogen IdecRocheJohnson and JohnsonMerckMitsubishi Tanabe PharmaNovartisPfizer

This research report has all the information you need to device optimum market strategies.

Production Analysis: The study includes a SWOT analysis of key market players in the Rheumatoid Arthritis and Lupus Treatments industry to assess their Strengths, Weaknesses, Opportunities, Threats, and examines the companys internal & external environments and the elements present that could affect the growth of the industry.

In market segmentation by types of Rheumatoid Arthritis and Lupus Treatments, the report covers-

Rheumatoid Arthritis TreatmentsLupus Treatments

The evaluation also includes the rates of production and consumption, gross revenue, and average product price and market shares of key players. The information gathered is further broken down by including regional markets, production plants, and product types available in the market. Other key points, like competitive analysis and trends, concentration rate, mergers & acquisitions, expansion tactics, which are vital to establishing a business in the sector, have also been included in the report.

In market segmentation by applications of the Rheumatoid Arthritis and Lupus Treatments, the report covers the following uses-

Hospitals and ClinicsAmbulatory Surgery CentersHomecare Settings

To get this report at incredible Discounts or for Report Customization, reach out to [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/53445

Manufacturing Analysis:The report gives an extensive analysis of various segments of the market by studying the product range, applications, major regions, and leading companies in the industry. Additionally, the report also dedicates an individual section to give a detailed analysis of the manufacturing process, which includes information collected through both primary and secondary sources of data collection. The primary source of data collection contains interviews of industry experts who offer accurate insights into the future market scenario.

Sales and Revenue Estimation:By employing both top-down and bottom-up approaches to evaluate the past data relating to the sales and revenue, along with the current market scenario. Our team of analysts predicts the future growth of the market and the development of the market in the leading geographies. The study also includes a comprehensive study of the product types, applications, end-users, leading regions, and critical participants in the industry. It also offers other critical data relating to the regulatory framework and guidelines, along with the macro-economic indicators influencing the growth of the market through detailed market estimation.

Rheumatoid Arthritis and Lupus Treatments Market Regional landscape includes: North AmericaAsia-PacificEuropeLatin AmericaMiddle East & Africa

Demand & Supply Assessment:The report also offers key highlights relating to the manufacturing processes, along with a cost analysis, rates of consumption and production, import/export status, product range, and supply chain assessment.

Competitive landscape:The report sheds light on critical information relating to the company profiles, product portfolio, growth prospects, cost assessment, total sales, revenue generated, market shares held by key regions, established companies, and emerging players.

To buy this report, [emailprotected] https://www.marketexpertz.com/checkout-form/53445

The Rheumatoid Arthritis and Lupus Treatments market report provides accurate market insights into the inclination in consumer preferences and behavior, along with an overview of the market data and major companies. The study offers all relevant information to help readers optimize on the market opportunities and formulate lucrative business strategies.

The Rheumatoid Arthritis and Lupus Treatments Market Research/Analysis Report addresses the following questions:

Request for Free Sample Report To Understand the structure of the complete [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/53445

In conclusion, the Rheumatoid Arthritis and Lupus Treatments Market report is a reliable source for accessing the Market data that will exponentially accelerate your business. The report provides the principal locale, economic scenarios with the item value, benefit, supply, limit, generation, request, Market development rate, and figure and so on. Besides, the report presents a new task SWOT analysis, speculation attainability investigation, and venture return investigation.

Original post:
Rheumatoid Arthritis and Lupus Treatments Market Share, Trends and Leading Players By 2026 - News Times

As JIA-associated uveitis (JIAU) is asymptomatic in the majority of patients, ophthalmologic screening examinations are recommended, depending on the risk constellation for uveitis development. This study analyses disease characteristics in JIAU depending on adherence with the screening intervals.953 patients were included in the ICON registry. In patients without uveitis, ophthalmologic screening was recommended in accordance with the standards currently applied in Germany. Dates and results of the screening examinations were noted for each patient.Until the 3-year-follow up, uveitis developed in 133 of 953 JIA patients. In 56 of them, uveitis was present before study inclusion, and those were excluded from the prospective analysis. For the remaining 897 JIA patients, screening results were available in 557, 46 of whom developed uveitis. In those patients, adherence with the suggested screening intervals until uveitis onset was assessed, and patients were classified accordingly: screenings as recommended (Sc+ group, n=356) vs. infrequent screening (Sc- group, n=201). Non-adherence with the screening schedule significantly correlated with younger age at study inclusion and JIA diagnosis, shorter JIA disease duration, JIA oligoarthritis subtype and positive antinuclear antibody status. The Sc+ group had a better visual acuity (VA) at initial uveitis diagnosis, however, at the 3-year-follow up, VA and uveitis complication rates did not differ significantly.Especially high-risk patients often do not adhere to the initial frequently recommended screening intervals, resulting in a reduced visual acuity at initial uveitis diagnosis. A recommendation for changing the current screening intervals cannot be deduced from our data.

Read more:
Adherence to ophthalmological screening recommendations and course of uveitis in children with juvenile idiopathic arthritis: data from the Inception...

Over the past three decades, hand surgeon Scott Wolfe, who sees patients at Hospital for Special Surgery (HSS) in New York City and at HSS Stamford, has been conducting research to find a better way to repair a common wrist injury that results in pain and disability.

Now a new surgical procedure to repair a torn scapholunate ligament shows promise in relieving wrist pain and restoring function, according to Dr. Wolfe, Chief Emeritus of the Hand and Upper Extremity Service at HSS. He believes it may also prevent the arthritis that many people with the injury develop over time.

Forty-year-old Asad Spahic, a mechanical engineer from Southington, Connecticut, is among the patients who say the procedure has relieved their pain and enabled them to return to activities they enjoy.

The scapholunate is a critical ligament that connects and stabilizes the scaphoid and lunate, two small bones near the center of the wrist. When an injury, often a fall on an outstretched hand, causes the ligament to rupture, patients can experience pain, lose grip strength and develop arthritis that gets worse as time goes on.

"When the ligament tears, the scaphoid and lunate bones will separate, start to rotate and degenerate. Some patients can feel the scaphoid popping in and out of its normal position," Dr. Wolfe explains. Without treatment to repair the torn ligament, people ultimately develop a condition known as SLAC wrist. SLAC, which stands for "scapholunate advanced collapse," is the most common form of post-traumatic arthritis in the wrist, affecting about four million people. As the bones rub abnormally against each other, their protective cartilage wears away.

"The injury most often affects healthy active people. When the ligament ruptures, any activity that combines wrist motion and wrist strength becomes difficult, if not impossible," Dr. Wolfe says. "Affected patients report problems performing jobs that require manual work. They can no longer play sports such as golf or tennis, do yoga or Pilates, or work out with weights at the gym."

Until now, surgery to reconstruct a torn scapholunate ligament has not been ideal, Dr. Wolfe says. The most common repair, which entails the use of metal wires and pins, fails in about 30 percent of patients.

Dr. Wolfe is one of just a few hand surgeons in the U.S. performing the new procedure, known as ANAFAB (anatomic front and back repair). "The goal is to reconnect the bones and restore their normal motion to provide pain relief, make the wrist stable again and stop the arthritic process," he explains.

Dr. Wolfe describes the surgery as a complex and highly technical procedure. "The critical ligaments in the front and the back of the wrist are reconstructed by using a portion of one of the tendons in the patient's wrist, combined with a synthetic tape that's 10 times stronger than steel, weight for weight. The tape is very strong, but also very lightweight and very thin," he says. "The patient's own tendon and this synthetic material are woven through the bones in such a way that the scapholunate ligament, as well as two other nearby ligaments, are repaired all at once. This brings the bones back into the proper position and stabilizes them, so abnormal movement is stopped."

The new procedure is performed without the use of wires and pins, a major advantage, he says, as metal hardware in the wrist can loosen, become infected, fail and necessitate another surgery.

Dr. Wolfe has performed the ANAFAB procedure on 14 patients to date and is monitoring their progress. So far, so good. Asad Spahic, Dr. Wolfe's patient from Southington, found Dr. Wolfe online. His ligament injury, sustained nine years earlier, had led to worsening wrist instability and weakness. He enjoyed participating in sports, but his wrist felt like it was giving way during certain activities, and he began to experience a dull ache. X-rays showed that arthritis was developing.

"A local doctor said the arthritis would get worse, the longer I waited to have surgery. I searched online for the best doctor I could find, reading medical journals," Mr. Spahic said. He knew that once arthritis became severe, a wrist fusion was the standard procedure for pain relief, but a fusion would limit wrist motion and curtail his athletic activities.

He opted for the new surgery with Dr. Wolfe in May 2019. "My experience has been nothing short of phenomenal," Mr. Spahic says. "I don't even think about my wrist. I go skiing, I play soccer, although I use a wrist brace in case I fall because it's been less than a year since my surgery. I have zero pain, zero problems, and the same strength as in my other wrist."

Dr. Wolfe says he will continue to conduct follow-up to gauge the outcomes of ANAFAB surgery to see how patients fare over the long term. "The results are preliminary, but in my 30-year career I have not been this excited about this kind of ligament repair. We're seeing patients who are now pain-free and back to activities they enjoy."

# # #

About HSS

HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report "Best Children's Hospitals" list (2019-2020). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In addition, HSS will be opening a new facility in Florida in early 2020. In 2018, HSS provided care to 139,000 patients and performed more than 32,000 surgical procedures, and people from all 50 U.S. states and 80 countries travelled to receive care at HSS. There were more than 37,000 pediatric visits to the HSS Lerner Children's Pavilion for treatment by a team of interdisciplinary experts. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is the world's leading provider of education on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. http://www.hss.edu.

Continue reading here:
Local Hand Surgeon Helps Patients with Painful Wrist Injury - Patch.com

In this new business intelligence Rheumatoid Arthritis Treatment market report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Rheumatoid Arthritis Treatment market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Rheumatoid Arthritis Treatment market.

With having published myriads of Rheumatoid Arthritis Treatment market reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/22555

The Rheumatoid Arthritis Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the Rheumatoid Arthritis Treatment market players could create collaborations in a bid to sustain production footprint.

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/22555

What does the Rheumatoid Arthritis Treatment market report contain?

Readers can get the answers of the following questions while going through the Rheumatoid Arthritis Treatment market report:

And many more

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/22555

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Read the original:
Rheumatoid Arthritis Treatment Market Analysis and Forecast to 2026 by Recent Trends, Developments in Manufacturing Technology and Regional Growth...

As per a report Market-research, the Rheumatoid Arthritis Stem Cell Therapy economy is likely to see a CAGR increase of XX% within the forecast period (2019-2029) and reach at a value of US$ at the ending of 2029. The macro economic and micro elements which are predicted to influence the trajectory of this market are examined from the market analysis that was presented.

Light onto the material throws Providers, vendors, manufacturers, and market participants at the value string of their industry that is Rheumatoid Arthritis Stem Cell Therapy . Whats more, its particular influence on the market and the political and economic scenarios of regions are discussed within the analysis.

Critical Details included from this record:

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Competitive Outlook

Light onto the throws Business prospects of players operating from the industry that is Rheumatoid Arthritis Stem Cell Therapy . The item pricing plans, marketing stations that were preferred and product portfolio of most players, and promote presence of every and every provider is contained in the title. The players comprise Business 4, Business two, Business 3, and Business.

Regional Assessment

The marketplace research that is introduced sheds light onto the Marketplace Scenario in numerous markets. Additionally, the effects of the governmental and regulatory policies to this market in every regions prospects is examined from the report.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

The report Suits the questions pertaining Into the Rheumatoid Arthritis Stem Cell Therapy economy:

Reasons Fact.MR Sticks out

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Original post:
Rheumatoid Arthritis Stem Cell Therapy Market Key Development by 2025 - News Times

Anti-interleukin-1 (anti-IL-1) agents anakinra and canakinumab may be safe and effective in the treatment of familial Mediterranean fever (FMF), according to study results published in Advances in Rheumatology. Researchers showed that these anti IL-1 agents were effective in reducing proteinuria but less effective in cases with FMF associated with arthritis and sacroiliitis.

Colchicine is typically the primary treatment for FMF attacks and amyloidosis; however, 5% to 15% of patients become resistant/unresponsive to colchicine for whom biologic agents including anti-IL-1 are indicated. In this study, the researchers investigated the safety and efficacy of anakinra and canakinumab in patients with colchicine-resistant FMF.

Investigators enrolled 65 patients (median age, 32 years [range, 17-60 years]; 50.8% men) from the Sivas Cumhuriyet University between January 2014 and March 2019 who were diagnosed with FMF, according to Tel-Hashomer criteria, and had colchicine resistance/intolerance. Researchers collected data from laboratory values, clinical features, and disease activities, and analyzed the information every 3 months. More than half (63.1%) of the patients received anakinra (100 mg/d subcutaneous) and 36.9% of the patients received canakinumab (150 mg/8 week subcutaneous). Median duration of the anti-IL-1 agents was 6 and 8 months for anakinra and canakinumab, respectively.

Researchers found a statistically significant improvement in the visual analog scale, erythrocyte sedimentation rate, C-reactive protein, and attack duration with anti-IL-1 treatment. A total of 96.9% patients (n=63) achieved FMF-50 score response for the anti-IL-1 treatments. Anti-IL-1 agents significantly decreased proteinuria in patients with glomerular filtration rate 60 mL/min/m2; the median proteinuria decreased from 2390 mg/d (range, 1400-7200 mg/d) to 890 mg/d (range, 120-2750 mg/d; P =.008). For the group with glomerular filtration rate <60 mL/min/m2, the median proteinuria decreased from 4472 mg/d (range, 1950-11,200 mg/d) to 3960 mg/d (range, 2050-12,200 mg/d), although the difference was not statistically significant (P =.345). In terms of safety issues, there were serious infections or tuberculosis or malignancy, except in 1 patient.

Study limitations included the small sample size, lack of a randomized controlled trial, and the fact that there was no adjustment for confounding factors such as blood pressure, use of angiotensin receptor blocker drugs, and diet.

[Randomized controlled trials] should be conducted to demonstrate the efficiency of the treatment in these clinical situations. Further studies are needed to determine the safety and long-term side effects of anti-IL-1 therapies, the researchers concluded.

Reference

Sahin A, Derin ME, Albayrak F, Karakas B, Karagoz Y. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020;60(1):12.

Continue reading here:
Anti-IL-1 Agents May Be Effective in the Treatment of Familial Mediterranean Fever in Patients With Colchicine Resistance/Intolerance - Rheumatology...

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the Company) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibes lead drug, ATB-346. The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis (OA) pain compared to placebo in 360 patients.

The final patients will be on treatment for two weeks, followed by a two-week monitoring period and analysis of the primary endpoint data. The primary endpoint in the study is the change in OA knee pain of ATB-346 versus placebo as measured by the WOMAC subscale pain score, considered the gold standard in pain assessment for arthritis trials. Patients have been randomized to placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.

The Company anticipates the release of top-line results within six weeks.

About ATB-346

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used therapy for osteoarthritis, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346.

About Antibe Therapeutics Inc.

Antibe develops safer, non-addictive medicines for pain and inflammation. Antibes technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibes lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibes pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. http://www.antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Companys inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Excerpt from:
Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346 - Business Wire